Yr Athro Neil Robertson

(Translated he/him)

MBBS FRCP MD

2026

• Zeng, L. et al., 2026. Genome-wide association analyses highlight the neuronal contribution to multiple sclerosis susceptibility. Nature Genetics 58 (9), pp.2177-2191. (10.1038/s41588-026-02731-7)
• Abbadessa, G. et al., 2026. Genetic subtypes of multiple sclerosis severity are uncoupled from inflammatory lesion burden. Acta Neuropathologica 152 24. (10.1007/s00401-026-03062-x)
• Kreft, K. L. et al. 2026. Genetic subtypes associated with multiple sclerosis severity and response to treatment. Journal of Neurology, Neurosurgery and Psychiatry 97 (5), pp.413-421. (10.1136/jnnp-2025-337337)
• de Keijzer, C. et al., 2026. Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries. Therapeutic Advances in Neurological Disorders 19 (10.1177/17562864261444676)
• Voase, S. et al., 2026. MOGAD in South Wales: Diagnostic evolution and disease epidemiology. European Journal of Neurology 33 (2) e70502. (10.1111/ene.70502)

2025

• Robertson, N. 2025. Alemtuzumab: balancing risks. Multiple Sclerosis Journal 31 (14), pp.1687-1688. (10.1177/13524585251365794)
• Kremler, C. et al., 2025. Real world outcomes of alemtuzumab in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 96 , pp.A42.3. (10.1136/jnnp-2025-ABN.139)
• Wood, C. et al., 2025. 47 Multiple sclerosis and seizures: clinical, diagnostic and therapeutic correlations [Abstract]. Journal of Neurology, Neurosurgery and Psychiatry 96 A15. (10.1136/jnnp-2025-abn.47)
• Griffiths, L. et al., 2025. Sterol imbalances and cholesterol-24-hydroxylase dysregulation is linked to the underlying progression of multiple sclerosis. Brain Pathology 35 (5) e70001. (10.1111/bpa.70001)
• Wood, C. et al., 2025. Multiple sclerosis and seizures: clinical, diagnostic and therapeutic correlations. Brain and Behavior 15 (5) e70511. (10.1002/brb3.70511)
• Davies, L. et al., 2025. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. Journal of Neurology 272 415. (10.1007/s00415-025-13133-w)
• Robertson, N. P. 2025. Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.. Journal of Neurology 272 (1) 106. (10.1007/s00415-025-12892-w)

2024

• Nicholas, R. et al., 2024. Algorithmic approach to finding people with multiple sclerosis using routine healthcare data in Wales. Journal of Neurology, Neurosurgery & Psychiatry 96 (11), pp.1032-1035. (10.1136/jnnp-2024-333532)
• Blackstone, J. et al., 2024. Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. BMJ Open 14 (9) e086414. (10.1136/bmjopen-2024-086414)
• Elias, M. , Robertson, N. P. and Hughes, T. 2024. New approaches in the management of intracranial haemorrhage. Journal of Neurology 271 , pp.6393–6395. (10.1007/s00415-024-12620-w)
• Roos, I. et al., 2024. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 30 (9), pp.1163-1175. (10.1177/13524585241267211)
• Tallantyre, E. C. et al. 2024. Real world persistence of multiple sclerosis disease modifying therapies. European Journal of Neurology 31 (7) e16289. (10.1111/ene.16289)
• Hawken, J. and Robertson, N. 2024. The role of optical coherence tomography in neurodegenerative disease. Journal of Neurology 271 (8), pp.5696–5698. (10.1007/s00415-024-12547-2)
• Uzochukwu, E. C. et al. 2024. Modelling disease progression of Multiple Sclerosis in a South Wales cohort. Neuroepidemiology 58 (3), pp.218-226. (10.1159/000536427)
• Nasir, M. et al., 2024. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders 85 105528. (10.1016/j.msard.2024.105528)
• Voase, S. and Robertson, N. P. 2024. Diagnostic criteria for MOGAD. Journal of Neurology 271 (6), pp.3690-3692. (10.1007/s00415-024-12405-1)
• Zid, Y. and Robertson, N. P. 2024. Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials. Journal of Neurology 271 (4), pp.2141-2143. (10.1007/s00415-024-12273-9)
• Kreft, K. L. et al. 2024. Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort. Annals of Neurology 95 (3), pp.459-470. (10.1002/ana.26831)
• Kodosaki, E. et al. 2024. Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes. Journal of Neuroinflammation 21 (1) 52. (10.1186/s12974-024-03036-4)
• Harding, K. E. et al. 2024. Prodromal multiple sclerosis: considerations and future utility. Journal of Neurology 271 (4), pp.2129-2140. (10.1007/s00415-023-12173-4)
• Saw, A. , Bari, S. and Robertson, N. P. 2024. Novel biomarkers and neuroimaging techniques in Parkinson’s disease. Journal of Neurology 271 , pp.1056-1058. (10.1007/s00415-024-12187-6)

2023

• Voase, S. and Robertson, N. P. 2023. Cavernomas: to treat or not to treat?. Journal of Neurology 271 (1), pp.618-620. (10.1007/s00415-023-12115-0)
• Sheppard, J. , Wynford-Thomas, R. and Robertson, N. P. 2023. “Navigating the network”: Localising the lesion with the advent of lesion network mapping. Journal of Neurology 270 (12), pp.6207-6209. (10.1007/s00415-023-12059-5)
• Bari, S. and Robertson, N. P. 2023. MRI-guided focused ultrasound: new hope for drug-resistant neurological conditions. Journal of Neurology 270 (11), pp.5671-5673. (10.1007/s00415-023-12024-2)
• Mahmood, A. , Hawken, J. and Robertson, N. P. 2023. Clinical trials in myasthenia gravis. Journal of Neurology 270 (9), pp.4579-4581. (10.1007/s00415-023-11903-y)
• Solomon, A. J. et al., 2023. Global barriers to the diagnosis of multiple sclerosis. Neurology 101 (6), pp.e624-e635. (10.1212/WNL.0000000000207481)
• Zaloum, S. et al., 2023. Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination. Multiple Sclerosis Journal 29 (8), pp.979-989. (10.1177/13524585231185247)
• Chen, B. et al., 2023. Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD?. Annals of Neurology 94 (3), pp.508-517. (10.1002/ana.26731)
• Saw, A. M. , Hrastelj, J. and Robertson, N. P. 2023. Path from discovery to recovery: therapeutic and diagnostic advances in Alzheimer's dementia. Journal of Neurology 270 (8), pp.4151-4153. (10.1007/s00415-023-11840-w)
• Lewis, C. et al. 2023. Social support as a predictor of outcomes of cognitive behavioral therapy with a trauma focus delivered face-to-face and via guided internet-based self-help. Journal of Traumatic Stress 36 (3), pp.511-523. (10.1002/jts.22947)
• Schroeder, B. E. , Robertson, N. P. and Hughes, T. A. T. 2023. Cerebral amyloid angiopathy: an update. Journal of Neurology 270 , pp.2809-2811. (10.1007/s00415-023-11631-3)
• Harding, K. E. et al., 2023. Contemporary study of multiple sclerosis disability in South East Wales. Journal of Neurology, Neurosurgery and Psychiatry 94 (4), pp.272-279. (10.1136/jnnp-2022-330013)
• Robertson, N. P. 2023. Advances in Tourette’s syndrome. Journal of Neurology 270 (3), pp.1808-1810. (10.1007/s00415-023-11588-3)
• Wynford-Thomas, R. and Robertson, N. P. 2023. Amyotrophic lateral sclerosis: an update on treatments from clinical trials. Journal of Neurology 270 (2), pp.1187-1189. (10.1007/s00415-022-11553-6)
• Majumder, S. N. , Hrastelj, J. and Robertson, N. P. 2023. Advances in the genetics of stroke risk and recovery. Journal of Neurology 270 (1), pp.590-591. (10.1007/s00415-022-11525-w)

2022

• Beesley, R. et al., 2022. Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies. Multiple Sclerosis and Related Disorders 68 104121. (10.1016/j.msard.2022.104121)
• Hawken, J. and Robertson, N. 2022. Sleep disorders in Parkinson’s disease. Journal of Neurology 269 , pp.6685-6687. (10.1007/s00415-022-11403-5)
• Walz, L. et al., 2022. Life expectancy in multiple sclerosis by EDSS score. Multiple Sclerosis and Related Disorders 68 104219. (10.1016/j.msard.2022.104219)
• Miah, L. and Robertson, N. 2022. The gut microbiome: neurological development and disease. Journal of Neurology 269 (10), pp.5682-5684. (10.1007/s00415-022-11334-1)
• Kreft, K. L. and Robertson, N. P. 2022. Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment. Journal of Neurology 269 (9), pp.5192-5193. (10.1007/s00415-022-11300-x)
• Tallantyre, E. C. et al. 2022. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.. Multiple Sclerosis and Related Disorders 64 103937. (10.1016/j.msard.2022.103937)
• Gailani, G. and Robertson, N. P. 2022. Clinical patterns in CADASIL. Journal of Neurology 269 (8), pp.4575-4577. (10.1007/s00415-022-11261-1)
• Hrastelj, J. and Robertson, N. P. 2022. Socioeconomic status in neurological disorders: a modifiable risk factor?. Journal of Neurology 269 (6), pp.3385-3386. (10.1007/s00415-022-11123-w)
• Hrastelj, J. and Robertson, N. P. 2022. A role for the Epstein–Barr virus in multiple sclerosis aetiology?. Journal of Neurology 269 (7), pp.3962-3963. (10.1007/s00415-022-11177-w)
• Schroeder, B. E. and Robertson, N. P. 2022. Clinical trials for cerebellar ataxia. Journal of Neurology 269 (5), pp.2819–2821. (10.1007/s00415-022-11088-w)
• Allman, M. , Tallantyre, E. and Robertson, N. P. 2022. Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies. Journal of Neurology 269 (4), pp.2259-2261. (10.1007/s00415-022-11053-7)
• Thomas, R. , Wynford-Thomas, R. and Robertson, N. P. 2022. Advances in the use of stem cell transplants in the treatment of multiple sclerosis. Journal of Neurology 269 (2), pp.1065–1067. (10.1007/s00415-021-10927-6)
• Wood, C. H. et al. 2022. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate. Multiple Sclerosis and Related Disorders 58 103492. (10.1016/j.msard.2022.103492)
• Cauchi, M. et al. 2022. Interpretation of vaccine associated neurological adverse events: a methodological and historical review. Journal of Neurology 269 , pp.493-503. (10.1007/s00415-021-10747-8)
• Talaei, M. and Robertson, N. P. 2022. Intravenous immunoglobulin for inflammatory demyelinating polyneuropathy. Journal of Neurology 269 (1), pp.534-536. (10.1007/s00415-021-10908-9)
• Tallantyre, E. et al. 2022. COVID-19 vaccine response in people with multiple sclerosis. Annals of Neurology 91 (1), pp.89-100. (10.1002/ana.26251)

2021

• Williams, S. , Wynford-Thomas, R. and Robertson, N. P. 2021. Long-COVID: neurological manifestations and management. Journal of Neurology 268 (12), pp.4915–4917. (10.1007/s00415-021-10847-5)
• Hrastelj, J. and Robertson, N. P. 2021. Vaccine-induced immune thrombosis and thrombocytopaenia: incidence, mechanism and treatment. Journal of Neurology 268 (11), pp.4396-4397. (10.1007/s00415-021-10825-x)
• Al-Ansari, A. and Robertson, N. P. 2021. Autoimmune encephalitis: clinical presentation, investigation and treatment. Journal of Neurology 268 (10), pp.3935–3937. (10.1007/s00415-021-10800-6)
• Massey, T. H. and Robertson, N. P. 2021. Medication-overuse headache: causes, consequences and management. Journal of Neurology 268 (9), pp.3505–3507. (10.1007/s00415-021-10720-5)
• Al-Ansari, A. and Robertson, N. P. 2021. Postural orthostatic tachycardia syndrome: insights into pathogenesis and treatment. Journal of Neurology 268 (7), pp.2616–2618. (10.1007/s00415-021-10649-9)
• Winter, M. et al. 2021. Tract-specific MRI measures explain learning and recall differences in multiple sclerosis. Brain Communications 3 (2) fcab065. (10.1093/braincomms/fcab065)
• Hrastelj, J. et al. 2021. CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis. Brain Communications (10.1093/braincomms/fcab155)
• Hares, K. et al., 2021. KIF5A and the contribution of susceptibility genotypes as a predictive biomarker for multiple sclerosis. Journal of Neurology 268 , pp.2175-2184. (10.1007/s00415-020-10373-w)
• Lipp, I. et al. 2021. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: a behavioural and MRI study. Multiple Sclerosis 7 (7), pp.1088-1101. (10.1177/1352458520943788)
• Cauchi, M. and Robertson, N. P. 2021. Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2. Journal of Neurology 268 , pp.2002-2004. (10.1007/s00415-021-10513-w)
• Massey, T. H. and Robertson, N. P. 2021. Spontaneous intracranial hypotension: features, diagnosis and management. Journal of Neurology 268 (4), pp.1555-1557. (10.1007/s00415-021-10500-1)

2020

• Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26 (14), pp.1929-1937. (10.1177/1352458519887905)
• Willis, M. D. and Robertson, N. P. 2020. Multiple sclerosis: early indicators of disease and assessing future risk. Journal of Neurology 267 (11), pp.3436-3438. (10.1007/s00415-020-10239-1)
• Naughton, M. et al., 2020. CCN3 is dynamically regulated by treatment and disease state in multiple sclerosis. Journal of Neuroinflammation 17 (1) 349. (10.1186/s12974-020-02025-7)
• Walton, C. et al., 2020. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis 26 (14), pp.1816-1821. (10.1177/1352458520970841)
• Al-Ansari, A. and Robertson, N. P. 2020. Cerebral venous thrombosis: clinical predictors and emerging treatments. Journal of Neurology 267 (10), pp.3112–3114. (10.1007/s00415-020-10180-3)
• Anderson, V. et al. 2020. Serum neurofilament-light concentration and real-world outcome in MS. Journal of the Neurological Sciences 417 117079. (10.1016/j.jns.2020.117079)
• Wynford-Thomas, R. and Robertson, N. P. 2020. Emerging treatments for neuromyelitis optica spectrum disorder. Journal of Neurology 267 (9), pp.2771-2773. (10.1007/s00415-020-10083-3)
• Hu, M. and Robertson, N. P. 2020. Physical activity as a risk factor for amyotrophic lateral sclerosis-findings from three large European cohorts. Journal of Neurology 267 (7), pp.2173-2175. (10.1007/s00415-020-09995-x)
• Saxena, G. et al., 2020. Detecting and predicting neutralization of alemtuzumab responses in multiple sclerosis. Neurology, Neuroimmunology and Neuroinflammation 7 (4) e767. (10.1212/NXI.0000000000000767)
• Yeo, T. et al., 2020. A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Scientific Reports 10 12381. (10.1038/s41598-020-69119-3)
• Tallantyre, E. et al. 2020. Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. Multiple Sclerosis and Related Disorders 42 102056. (10.1016/j.msard.2020.102056)
• Pryce-Roberts, A. , Talaei, M. and Robertson, N. P. 2020. Neurological complications of COVID-19: a preliminary review. Journal of Neurology 267 (6), pp.1870-1873. (10.1007/s00415-020-09941-x)
• Willis, M. D. and Robertson, N. P. 2020. Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. Journal of Neurology 267 (5), pp.1567-1569. (10.1007/s00415-020-09822-3)
• McLauchlan, D. and Robertson, N. P. 2020. Chronic traumatic encephalopathy: quantifying risk and clarifying pathogenesis. Journal of Neurology 267 (3), pp.870-872. (10.1007/s00415-020-09734-2)
• Massey, T. H. and Robertson, N. P. 2020. Restless legs syndrome: causes and consequences. Journal of Neurology 267 (2), pp.575-577. (10.1007/s00415-019-09682-6)

2019

• Davda, N. , Tallantyre, E. and Robertson, N. P. 2019. Early MRI predictors of prognosis in multiple sclerosis. Journal of Neurology 266 (12), pp.3171-3173. (10.1007/s00415-019-09589-2)
• Al-Ansari, A. and Robertson, N. P. 2019. Cluster headache: an overview of established and emerging treatments. Journal of Neurology 266 (11), pp.2890-2892. (10.1007/s00415-019-09548-x)
• Castle, D. and Robertson, N. P. 2019. Treatment of progressive multifocal leukoencephalopathy. Journal of Neurology 266 (10), pp.2587-2589. (10.1007/s00415-019-09501-y)
• Jones, L. et al. 2019. A case of treatment resistance and complications in a patient with stiff person syndrome and cerebellar ataxia. Tremor and Other Hyperkinetic Movements 9 (10.7916/tohm.v0.677)
• Castle, D. and Robertson, N. P. 2019. Alternatives to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neurology 266 (9), pp.2338-2340. (10.1007/s00415-019-09485-9)
• Muller, I. et al. 2019. 2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. European Thyroid Journal 8 (4), pp.173-185. (10.1159/000500881)
• Willis, M. D. and Robertson, N. P. 2019. Neurotoxicity of novel cancer immunotherapies. Journal of Neurology 266 (8), pp.2087-2089. (10.1007/s00415-019-09444-4)
• Lipp, I. et al. 2019. Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis. Human Brain Mapping 40 (10), pp.2917-2932. (10.1002/hbm.24568)
• Hu, M. et al., 2019. Perceived fatigue and cognitive performance change in multiple sclerosis: Uncovering predictors beyond baseline fatigue. Multiple Sclerosis and Related Disorders 32 , pp.46-53. (10.1016/j.msard.2019.04.011)
• Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25 (4), pp.523-531. (10.1177/1352458518758927)
• Harding, K. E. et al. 2019. Socioeconomic status and disability progression in multiple sclerosis: a multinational study. Neurology 92 (13), pp.e1497-e1506. (10.1212/WNL.0000000000007190)
• Harding, K. et al. 2019. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurology 76 (5), pp.536-541. (10.1001/jamaneurol.2018.4905)
• Palace, J. et al., 2019. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme. Journal of Neurology, Neurosurgery and Psychiatry 90 (36), pp.251-260. (10.1136/jnnp-2018-318360)
• Smith, M. D. , Schwartz, S. and Robertson, N. P. 2019. Imaging in the diagnosis of progressive supranuclear palsy. Journal of Neurology 266 (2), pp.545-547. (10.1007/s00415-018-9148-5)
• Whittam, D. H. et al., 2019. Rituximab in neurological disease: principles, evidence and practice. Practical Neurology 19 (1), pp.5-10. (10.1136/practneurol-2018-001899)
• Brown, J. W. L. et al., 2019. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. Journal of the American Medical Association 321 (2), pp.175-187. (10.1001/jama.2018.20588)
• Harding, K. E. and Robertson, N. P. 2019. New rare genetic variants in multiple sclerosis. Journal of Neurology 266 (1), pp.278-280. (10.1007/s00415-018-9128-9)
• Al-Ansari, A. and Robertson, N. P. 2019. Autoimmune encephalitis: frequency and prognosis. Journal of Neurology 266 (5), pp.1287-1289. (10.1007/s00415-019-09273-5)
• Willis, M. and Robertson, N. 2019. Technology-assisted recovery of walking after spinal cord injury. Journal of Neurology 266 (4), pp.1046-1048. (10.1007/s00415-019-09227-x)

2018

• Muller, I. et al. 2018. Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years.. Thyroid 28 (12), pp.1682-1693. (10.1089/thy.2018.0232)
• Tallantyre, E. C. , Robertson, N. P. and Jolles, S. 2018. Secondary antibody deficiency in neurology. Current Opinion in Allergy and Clinical Immunology 18 (6), pp.481-488. (10.1097/ACI.0000000000000485)
• Al-Ansari, A. and Robertson, N. P. 2018. Anti-epileptics and pregnancy: an update. Journal of Neurology 265 (11), pp.2749-2751. (10.1007/s00415-018-9058-6)
• Beesley, R. et al., 2018. Impact of the 2017 revisions to McDonald criteria on the diagnosis of Multiple Sclerosis. Multiple Sclerosis 24 (13), pp.1786-1787. (10.1177/1352458518778007)
• Willis, M. D. et al. 2018. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis 24 (13), pp.1779-`782. (10.1177/1352458518790391)
• Harding, K. et al. 2018. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple Sclerosis and Related Disorders 25 , pp.186-191. (10.1016/j.msard.2018.08.001)
• Tallantyre, E. C. et al. 2018. How common is truly benign MS in a UK population?. Journal of Neurology, Neurosurgery and Psychiatry 90 , pp.522-528. (10.1136/jnnp-2018-318802)
• Pickrell, W. O. and Robertson, N. P. 2018. New treatments in Alzheimer's disease. Journal of Neurology 265 (9), pp.2162-2163. (10.1007/s00415-018-9018-1)
• Pariani, N. et al., 2018. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Journal of Clinical Endocrinology & Metabolism 108 (8), pp.3010-3018. (10.1210/jc.2018-00359)
• Willis, M. D. and Robertson, N. P. 2018. Myelin oligodendrocyte glycoprotein antibody-associated disease: characterising clinical disease. Journal of Neurology 265 (8), pp.1950-1952. (10.1007/s00415-018-8963-z)
• Loveless, S. et al. 2018. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology 28 (4), pp.507-520. (10.1111/bpa.12546)
• Hu, M. and Robertson, N. P. 2018. Transmissible amyloid protein: evidence from iatrogenic CJD. Journal of Neurology 265 (7), pp.1726-1729. (10.1007/s00415-018-8927-3)
• Castle, D. and Robertson, N. P. 2018. Monoclonal antibodies for migraine: an update. Journal of Neurology 265 (6), pp.1491-1492. (10.1007/s00415-018-8886-8)
• Alsaeed, M. et al., 2018. Multiple sclerosis: long-term outcomes in ethnic minorities. analysis of a UK population-based registry. European Journal of Neurology 25 (4), pp.701-704. (10.1111/ene.13571)
• McLauchlan, D. and Robertson, N. P. 2018. Stem cells in the treatment of central nervous system disease. Journal of Neurology 265 (4), pp.984-986. (10.1007/s00415-018-8818-7)
• Tallantyre, E. et al. 2018. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. Journal of Neurology 265 (5), pp.1115-1122. (10.1007/s00415-018-8812-0)
• Massey, T. and Robertson, N. 2018. Repurposing drugs to treat neurological diseases. Journal of Neurology 265 (2), pp.446-448. (10.1007/s00415-018-8732-z)
• Edwards, M. and Robertson, N. 2018. Seizures in Alzheimer's disease: is there more beneath the surface?. Journal of Neurology 265 (1), pp.226-228. (10.1007/s00415-017-8694-6)

2017

• Pickrell, W. O. and Robertson, N. P. 2017. Cannabidiol as a treatment for epilepsy. Journal of Neurology 264 (12), pp.2506-2508. (10.1007/s00415-017-8663-0)
• Harding, K. and Robertson, N. 2017. Epidemiology of progressive multiple sclerosis. In: Wilkins, A. ed. Progressive Multiple Sclerosis. Springer. , pp.31-47. (10.1007/978-3-319-65921-3_2)
• Wynford-Thomas, R. and Robertson, N. 2017. The economic burden of chronic neurological disease. Journal of Neurology 264 (11), pp.2345-2347. (10.1007/s00415-017-8632-7)
• McLauchlan, D. , Malik, G. A. and Robertson, N. P. 2017. Cerebral amyloid angiopathy: subtypes, treatment and role in cognitive impairment. Journal of Neurology 264 , pp.2184-2186. (10.1007/s00415-017-8608-7)
• Welton, J. L. et al., 2017. Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. Journal of Extracellular Vesicles 6 (1) 1369805. (10.1080/20013078.2017.1369805)
• Hrastelj, J. and Robertson, N. 2017. Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies. Journal of Neurology 264 (9), pp.2040-2042. (10.1007/s00415-017-8584-y)
• Crawshaw, A. A. and Robertson, N. P. 2017. The role of TSPO PET in assessing neuroinflammation. Journal of Neurology 264 (8), pp.1825-1827. (10.1007/s00415-017-8565-1)
• Massey, T. and Robertson, N. 2017. Why antisense could make sense for neurodegeneration. Journal of Neurology 264 (7), pp.1542-1544. (10.1007/s00415-017-8515-y)
• Hakobyan, S. et al. 2017. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 23 (7), pp.946-955. 135245851666900. (10.1177/1352458516669002)
• Harding, K. et al. 2017. Seasonal variation in multiple sclerosis relapse. Journal of Neurology 264 (6), pp.1059-1067. (10.1007/s00415-017-8485-0)
• Willis, M. D. and Robertson, N. P. 2017. Chronic traumatic encephalopathy: identifying those at risk and understanding pathogenesis. Journal of Neurology 264 (6), pp.1298-1300. (10.1007/s00415-017-8508-x)
• Absoud, M. et al., 2017. A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technology Assessment 21 31. (10.3310/hta21310)
• Al-Ansari, A. and Robertson, N. 2017. Creutzfeldt-Jacob disease: new directions in diagnosis and therapeutics. Journal of Neurology 264 (5), pp.1029-1031. (10.1007/s00415-017-8473-4)
• Kalincik, T. et al., 2017. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology 16 (4), pp.271-281. (10.1016/S1474-4422(17)30007-8)
• Robertson, N. and Peall, K. J. 2017. Dystonia: opportunities to gain insights into underlying pathophysiological mechanisms. Journal of Neurology 264 (3), pp.616-618. (10.1007/s00415-017-8411-5)
• Willis, M. et al. 2017. An observational study of alemtuzumab following fingolimod for multiple sclerosis. Neuroimmunology and Neuroinflammation 4 (2) E320. (10.1212/NXI.0000000000000320)
• Marouli, E. et al., 2017. Rare and low-frequency coding variants alter human adult height. Nature 542 , pp.186-190. (10.1038/nature21039)
• Malik, G. A. and Robertson, N. P. 2017. Treatments in Alzheimer's disease. Journal of Neurology 264 (2), pp.416-418. (10.1007/s00415-017-8395-1)
• Jones, L. and Robertson, N. 2017. An update on treatments in myasthenia gravis. Journal of Neurology 264 (1), pp.205-207. (10.1007/s00415-016-8359-x)
• McLauchlan, D. and Robertson, N. P. 2017. B cell treatments for multiple sclerosis. Journal of Neurology 264 (4), pp.814-816. (10.1007/s00415-017-8442-y)

2016

• Thomas, R. H. and Robertson, N. 2016. What can rare variant genetics tell us about cognition and intellectual difficulties?. Journal of Neurology 263 (12), pp.2565-2566. (10.1007/s00415-016-8326-6)
• Tilling, K. et al., 2016. Modelling disease progression in relapsing?remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technology Assessment 20 (81)(10.3310/hta20810)
• Clement, M. et al. 2016. Targeted suppression of autoreactive CD8+ T-cell activation using blocking anti-CD8 antibodies. Scientific Reports 6 35332. (10.1038/srep35332)
• Hrastelj, J. and Robertson, N. 2016. Ice bucket challenge bears fruit for amyotrophic lateral sclerosis. Journal of Neurology 263 (11) 2355. (10.1007/s00415-016-8297-7)
• Willis, M. et al. 2016. Alemtuzumab-induced remission of multiple sclerosis-associated uveitis. International Ophthalmology (10.1007/s10792-016-0370-9)
• Pickrell, W. O. and Robertson, N. 2016. Stem cell treatment for multiple sclerosis. Journal of Neurology 263 (10), pp.2145-2147. (10.1007/s00415-016-8284-z)
• Davies, F. et al. 2016. The transition to secondary progressive multiple sclerosis: an exploratory qualitative study of health professionals' experiences. International Journal of MS Care 18 (5), pp.257-264. (10.7224/1537-2073.2015-062)
• Thomas, R. H. and Robertson, N. 2016. The consequences of valproate exposure in utero. Journal of Neurology 263 (9), pp.1887-1889. (10.1007/s00415-016-8269-y)
• Willis, M. and Robertson, N. 2016. Alemtuzumab for multiple sclerosis. Current Neurology and Neuroscience Reports 16 84. (10.1007/s11910-016-0685-y)
• Rodríguez Cruz, P. M. et al., 2016. Time and region-specific season of birth effects in multiple sclerosis in the United Kingdom. JAMA Neurology 73 (8), pp.954-960. (10.1001/jamaneurol.2016.1463)
• Peall, K. J. and Robertson, N. 2016. Idiopathic rapid eye movement sleep behaviour disorder: a potential gateway to the development of disease-modifying treatments in neurodegenerative disorders. Journal of Neurology 263 (8), pp.1678-1680. (10.1007/s00415-016-8235-8)
• Willis, M. et al. 2016. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Multiple Sclerosis Journal 22 (9), pp.1215-1223. 1352458515614092. (10.1177/1352458515614092)
• Watkins, L. M. et al., 2016. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13 161. (10.1186/s12974-016-0611-x)
• McLauchlan, D. J. and Robertson, N. 2016. Reversing the trend: interventions to treat intracranial haemorrhage associated with anticoagulation. Journal of Neurology 263 (7), pp.1468-1470. (10.1007/s00415-016-8198-9)
• Massey, T. and Robertson, N. 2016. Zika virus and neurology: proving cause and effect. Journal of Neurology 263 (6), pp.1255-1257. (10.1007/s00415-016-8165-5)
• Harding, K. and Robertson, N. 2016. Deep brain stimulation for dystonia. Journal of Neurology 263 (5), pp.1045-1046. (10.1007/s00415-016-8137-9)
• Tallantyre, E. C. and Robertson, N. P. 2016. Continuous evolution of magnetic resonance imaging in multiple sclerosis. Journal of Neurology 263 (4), pp.835-837. (10.1007/s00415-016-8099-y)
• Butterworth, S. E. , Ingram, G. and Robertson, N. 2016. Advances in biomarker research in multiple sclerosis [Journal Club]. Journal of Neurology 263 (3), pp.621-623. (10.1007/s00415-016-8062-y)
• Mitchell, C. J. and Robertson, N. 2016. New ways of looking at an old disease: the reimagination of epilepsy. Journal of Neurology 263 (2), pp.414-416. (10.1007/s00415-016-8025-3)
• Tallantyre, E. C. , Wardle, M. and Robertson, N. 2016. How to run a multiple sclerosis relapse clinic. Practical Neurology 16 (1), pp.62-69. (10.1136/practneurol-2015-001214)
• Cauchi, M. and Robertson, N. 2016. CGRP and migraine. Journal of Neurology 263 (1), pp.192-194. (10.1007/s00415-015-8000-4)

2015

• Wynford-Thomas, R. and Robertson, N. 2015. The role of skin biopsy in differentiating idiopathic Parkinson's disease from other types of parkinsonism. Journal of Neurology 262 (12), pp.2793-2795. (10.1007/s00415-015-7974-2)
• Healy, S. , Willis, M. and Robertson, N. P. 2015. Prognosis in multiple sclerosis and the unveiling of pathogenic clues. Journal of Neurology 262 (11), pp.2596-2598. (10.1007/s00415-015-7938-6)
• Lawton, M. et al., 2015. A longitudinal model for disease progression was developed and applied to multiple sclerosis. Journal of Clinical Epidemiology 68 (11), pp.1355-1365. (10.1016/j.jclinepi.2015.05.003)
• McLauchlan, D. J. and Robertson, N. 2015. Refining the phenotype of inborn errors of metabolism. Journal of Neurology 262 (10), pp.2396-2398. (10.1007/s00415-015-7917-y)
• Peall, K. J. and Robertson, N. 2015. Biomarkers in Alzheimer's Disease: understanding disease trajectory and therapeutic targets. Journal of Neurology 262 (9), pp.2195-2197. (10.1007/s00415-015-7881-6)
• Thomas, R. H. and Robertson, N. 2015. Testing new treatments for paediatric epilepsies. Journal of Neurology 262 (8), pp.1996-1998. (10.1007/s00415-015-7857-6)
• Davies, F. et al. 2015. "You are just left to get on with it": qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis. BMJ Open 5 (7) e007674. (10.1136/bmjopen-2015-007674)
• Hrastelj, J. and Robertson, N. 2015. Improving survival in amyotrophic lateral sclerosis: future treatments in a modern service. Journal of Neurology 262 (7), pp.1791-1793. (10.1007/s00415-015-7811-7)
• Harding, K. and Robertson, N. 2015. HIV-associated neurocognitive disorders. Journal of Neurology 262 (6), pp.1596-1598. (10.1007/s00415-015-7783-7)
• Absoud, M. et al., 2015. Protocol for a multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin versus standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). BMJ Open 5 (5) e008312. (10.1136/bmjopen-2015-008312)
• Palace, J. et al., 2015. Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator. Lancet Neurology 14 (5), pp.497-505. (10.1016/S1474-4422(15)00018-6)
• Williams, O. , Tallantyre, E. C. and Robertson, N. 2015. Traumatic brain injury: pathophysiology, clinical outcome and treatment. Journal of Neurology 262 (5), pp.1394-1396. (10.1007/s00415-015-7741-4)
• Ingram, G. and Robertson, N. P. 2015. Pathophysiology of neuropsychiatric disorders: moving forward. Journal of Neurology 262 (4), pp.1096-1098. (10.1007/s00415-015-7706-7)
• Willis, M. and Robertson, N. 2015. Alemtuzumab for the treatment of multiple sclerosis. Therapeutics and Clinical Risk Management 2015 (11), pp.525-534. (10.2147/TCRM.S80112)
• Amin, R. and Robertson, N. 2015. Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 262 (3), pp.789-791. (10.1007/s00415-015-7667-x)
• Harding, K. E. et al. 2015. Modelling the natural history of primary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 86 , pp.13-19. (10.1136/jnnp-2014-307791)
• Tallantyre, E. et al. 2015. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Multiple Sclerosis Journal 21 (1), pp.67-75. (10.1177/1352458514538333)
• Tallantyre, E. C. and Robertson, N. 2015. Acute stroke management. Journal of Neurology 262 (1), pp.239-242. (10.1007/s00415-014-7607-1)
• Fung, W. and Robertson, N. 2015. Natalizumab in MS: JC antibody index. Journal of Neurology 262 (2), pp.492-494. (10.1007/s00415-015-7641-7)
• Tuohy, O. et al., 2015. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. Journal of Neurology, Neurosurgery & Psychiatry 86 (2), pp.208-215. (10.1136/jnnp-2014-307721)
• Willis, M. et al. 2015. Site-specific clinical disease onset in multiple sclerosis. European Journal of Neurology 22 (4), pp.732-735. (10.1111/ene.12564)

2014

• Malik, G. and Robertson, N. 2014. Functional neurology: new directions in causes, prognosis and treatment. Journal of Neurology 261 (12), pp.2463-2465. (10.1007/s00415-014-7573-7)
• Elsone, L. et al., 2014. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Multiple Sclerosis Journal 20 (11), pp.1533-1540. (10.1177/1352458514525870)
• Thomas, R. H. and Robertson, N. 2014. Novel auto-antibody syndromes. Journal of Neurology 261 (10), pp.2043-2045. (10.1007/s00415-014-7497-2)
• Harding, K. et al. 2014. No temporal effect on disability in multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 85 (10), pp.e4.2. (10.1136/jnnp-2014-309236.10)
• Ingram, G. et al. 2014. Complement activation in MS: An immunohistochemical analysis. Journal of Neurology, Neurosurgery & Psychiatry 85 (10), pp.e4.13. (10.1136/jnnp-2014-309236.11)
• Willis, M. et al. 2014. Alemtuzumab: Long term follow-up in a single centre cohort. Journal of Neurology, Neurosurgery & Psychiatry 85 (10), pp.A1-A57. (10.1136/jnnp-2014-309236.8)
• McLauchlan, D. and Robertson, N. 2014. Reducing central nervous system complications associated with the human immunodeficiency virus. Journal of Neurology 261 (9), pp.1842-1845. (10.1007/s00415-014-7466-9)
• Peall, K. J. and Robertson, N. 2014. Narcolepsy: environment, genes and treatment. Journal of Neurology 261 (8), pp.1644-1646. (10.1007/s00415-014-7435-3)
• Willis, M. and Robertson, N. 2014. Drug safety evaluation of alemtuzumab for multiple sclerosis. Expert Opinion on Drug Safety 13 (8), pp.1115-1124. (10.1517/14740338.2014.928691)
• Azzopardi, L. et al., 2014. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 85 (7), pp.795-98. (10.1136/jnnp-2013-307042)
• Willis, M. and Robertson, N. 2014. Treatment paradigms in multiple sclerosis: who, when and how to treat?. Journal of Neurology 261 (7), pp.1444-1446. (10.1007/s00415-014-7420-x)
• Palace, J. and Robertson, N. 2014. Modifying disability in progressive multiple sclerosis. Lancet 383 (9936), pp.2189-2191. (10.1016/S0140-6736(13)62641-0)
• Robertson, N. and Scolding, N. J. 2014. Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab. Neurology 82 (24), pp.2150-2215. (10.1212/WNL.0000000000000530)
• Harding, K. and Robertson, N. 2014. Applications of next-generation whole exome sequencing. Journal of Neurology 261 (6), pp.1244-1246. (10.1007/s00415-014-7372-1)
• Ingram, G. et al. 2014. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2 53. (10.1186/2051-5960-2-53)
• Aguirregomozcorta, M. and Robertson, N. 2014. Pregnancy and drug use in neurological disease. Journal of Neurology 261 (4), pp.842-844. (10.1007/s00415-014-7312-0)
• Flower, M. D. and Robertson, N. 2014. POLG: a cause of intractable epilepsy. Journal of Neurology 261 (2), pp.446-448. (10.1007/s00415-014-7255-5)
• Amin, R. A. and Robertson, N. 2014. Risk and sub phenotype in Parkinson's disease. Journal of Neurology 261 (1), pp.245-7. (10.1007/s00415-013-7214-6)
• Ali, K. and Robertson, N. 2014. Evolving concepts in migraine. Journal of Neurology 261 (5), pp.1046-1048. (10.1007/s00415-014-7348-1)
• Ingram, G. and Robertson, N. 2014. Accurate diagnosis of inflammatory neuropathies. Journal of Neurology 261 (11), pp.2244-2246. (10.1007/s00415-014-7531-4)
• Luppe, S. and Robertson, N. 2014. MOG-IgG in neuromyelitis optica. Journal of Neurology 261 (3), pp.640-642. (10.1007/s00415-014-7277-z)
• Stewart, J. P. et al., 2014. Seroprevalence of molluscum contagiosum virus in German and UK populations. PLoS ONE 9 (2) e88734. (10.1371/journal.pone.0088734)

2013

• Pryce-Roberts, A. and Robertson, N. 2013. Possible treatment targets in Alzheimer's disease. Journal of Neurology 260 (12), pp.3193-6. (10.1007/s00415-013-7195-5)
• Beecham, A. H. et al., 2013. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics 45 (11), pp.1353-60. (10.1038/ng.2770)
• McLauchlan, D. and Robertson, N. 2013. Epigenetics of Huntington's disease. Journal of Neurology 260 (11), pp.2938-41. (10.1007/s00415-013-7158-x)
• Harding, K. and Robertson, N. 2013. Traumatic brain injury: risk factors and prognostic assessment. Journal of Neurology 260 (10), pp.2691-3. (10.1007/s00415-013-7106-9)
• Hubers, A. A. et al., 2013. Suicidal ideation in a European Huntington's disease population. Journal of Affective Disorders 151 (1), pp.248-58. (10.1016/j.jad.2013.06.001)
• Willis, M. and Robertson, N. 2013. Amyotrophic lateral sclerosis: new hope for an old disease?. Journal of Neurology 260 (9), pp.2441-3. (10.1007/s00415-013-7063-3)
• Ali, K. W. and Robertson, N. 2013. Lessons from preclinical disease. Journal of Neurology 260 (8), pp.2193-5. (10.1007/s00415-013-7055-3)
• McLauchlan, D. and Robertson, N. 2013. Epidemiological aspects of Guillain-Barre syndrome. Journal of Neurology 260 (7), pp.1942-5. (10.1007/s00415-013-7009-9)
• Harding, K. and Robertson, N. 2013. Assessment of long-term outcome in neurological disease. Journal of Neurology 260 (6), pp.1693-5. (10.1007/s00415-013-6966-3)
• Kronenberg, F. et al., 2013. Novel Loci Associated with Increased Risk of Sudden Cardiac Death in the Context of Coronary Artery Disease [Article]. PLoS ONE 8 (4), pp.e59905. (10.1371/journal.pone.0059905)
• Matthews, L. et al., 2013. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution [Article]. Neurology 80 (14), pp.1330-1337. (10.1212/WNL.0b013e3182887957)
• Anderson, J. T. and Robertson, N. 2013. Risk factors and cerebrovascular disease [Journal Article]. Journal of Neurology 260 (2), pp.692-694. (10.1007/s00415-013-6835-0)
• Cossburn, M. D. et al. 2013. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 80 (1), pp.55-61. (10.1212/WNL.0b013e31827b5927)
• Harding, K. et al. 2013. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. Journal of Neurology, Neurosurgery & Psychiatry 84 (2), pp.141-147. (10.1136/jnnp-2012-303996)
• Ingram, G. and Robertson, N. 2013. Antibody mediated encephalitis [Journal Article]. Journal of Neurology 260 (4), pp.1187-1190. (10.1007/s00415-013-6890-6)
• Moore, P. et al. 2013. Demographic and clinical factors associated with changes in employment in multiple sclerosis. Multiple Sclerosis Journal 19 (12), pp.1647-1654. (10.1177/1352458513481396)
• Peall, K. J. and Robertson, N. 2013. Parkinsonism, dementia and glucocerebrosidase mutations. Journal of Neurology 260 (5), pp.1441-1444. (10.1007/s00415-013-6923-1)
• Tallantyre, E. C. and Robertson, N. 2013. Autism and intellectual disability. Journal of Neurology 260 (3), pp.936-939. (10.1007/s00415-013-6861-y)

2012

• Cooper, J. D. et al., 2012. Seven newly identified loci for autoimmune thyroid disease. Human Molecular Genetics 21 (23), pp.5202-5208. (10.1093/hmg/dds357)
• Jostins, L. et al., 2012. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491 (7422), pp.119-124. (10.1038/nature11582)
• Becker, E. B. E. et al., 2012. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. Journal of Neurology, Neurosurgery & Psychiatry 83 (4), pp.437-440. (10.1136/jnnp-2011-301506)
• Cossburn, M. et al. 2012. The prevalence of neuromyelitis optica in South East Wales. European Journal of Neurology 19 (4), pp.655-659. (10.1111/j.1468-1331.2011.03529.x)
• Harding, K. et al. 2012. Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosis. Neuroscience Letters 526 (1), pp.15-19. (10.1016/j.neulet.2012.06.040)
• Harding, K. and Robertson, N. 2012. Stem cells: from animal models to clinical practice. Journal of Neurology 259 (6), pp.1257-1259. (10.1007/s00415-012-6555-x)
• Harding, K. and Robertson, N. 2012. The interaction between acquired mitochondrial disease and neurodegeneration. Journal of Neurology 259 (8), pp.1761-1763. (10.1007/s00415-012-6614-3)
• Harding, K. and Robertson, N. 2012. Understanding mechanisms and treatments for neuropathic disease. Journal of Neurology 259 (7), pp.1509-1511. (10.1007/s00415-012-6587-2)
• Hirst, C. L. et al. 2012. Temporal evolution of remission following multiple sclerosis relapse and predictors of outcome. Multiple Sclerosis Journal 18 (8), pp.1152-1158. (10.1177/1352458511433919)
• Hirst, C. L. and Robertson, N. 2012. There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - No. Multiple Sclerosis Journal 18 (7), pp.925-926. (10.1177/1352458512450089)
• Ingram, G. et al. 2012. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal 18 (10), pp.1401-1411. (10.1177/1352458512438238)
• Kendall, K. et al., 2012. 176 Intravascular B cell lymphoma: a case series [Conference Abstract]. Journal of Neurology, Neurosurgery & Psychiatry 83 (3), pp.e1-e1. (10.1136/jnnp-2011-301993.218)
• Kendall, K. and Robertson, N. 2012. Neuroimaging. Journal of Neurology 259 (9), pp.2009-2011. (10.1007/s00415-012-6652-x)
• Kendall, K. et al. 2012. A neurological presentation of intravascular B-cell lymphoma. Case Reports (10.1136/bcr-2012-006439)
• McLauchlan, D. J. and Robertson, N. 2012. Management of status epilepticus. Journal of Neurology 259 (10), pp.2261-2263. (10.1007/s00415-012-6673-5)
• Moore, P. et al. 2012. Multiple sclerosis relapses and depression. Journal of Psychosomatic Research 73 (4), pp.272-276. (10.1016/j.jpsychores.2012.08.004)
• Robertson, N. 2012. New and old: notable drug developments for clinical practice. Journal of Neurology 259 (5), pp.1003-1005. (10.1007/s00415-012-6518-2)
• Robertson, N. 2012. The C9ORF72 syndrome: implications for clinical practice. Journal of Neurology 259 (4), pp.794-796. (10.1007/s00415-012-6479-5)
• Willis, M. and Robertson, N. 2012. Aphasia: early classification, evaluation of existing therapy, and novel therapeutics. Journal of Neurology 259 (11), pp.2510-2512. (10.1007/s00415-012-6701-5)

2011

• Cossburn, M. D. et al. 2011. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77 (6), pp.573-579. (10.1212/WNL.0b013e318228bec5)
• Robertson, N. and The International Multiple Sclerosis Genetics Consortium, 2011. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: A multicenter case-control study. PLoS ONE 6 (4) e18813. (10.1371/journal.pone.0018813)
• Cossburn, M. D. et al. 2011. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Multiple Sclerosis Journal 18 (1), pp.45-54. (10.1177/1352458511417479)
• Sawcer, S. et al., 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476 (7359), pp.214-219. (10.1038/nature10251)
• Bennetto, L. et al., 2011. The relationship between relapse, impairment and disability in multiple sclerosis. Multiple Sclerosis Journal 17 (10), pp.1218-1224. (10.1177/1352458511407368)
• Ingram, G. et al. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112 (10), pp.2653-2654. (10.1002/jcb.23204)
• Wickremaratchi, M. M. et al. 2011. The motor phenotype of Parkinson's disease in relation to age at onset. Movement Disorders 26 (3), pp.457-463. (10.1002/mds.23469)

2010

• Ingram, G. et al., 2010. What is the risk of permanent disability from a multiple sclerosis relapse? [Letter]. Neurology 75 (9), pp.837. (10.1212/WNL.0b013e3181eeea87)
• Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133 (6), pp.1602-1611. (10.1093/brain/awq085)
• Ingram, G. et al. 2010. Validity of patient-derived disability and clinical data in multiple sclerosis. Multiple Sclerosis Journal 16 (4), pp.472-479. (10.1177/1352458509358902)
• Ban, M. et al., 2010. A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis. Genes and Immunity 11 (8), pp.660-664. (10.1038/gene.2010.36)
• Booth, D. R. et al., 2010. IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes and Immunity 11 (5), pp.397-405. (10.1038/gene.2010.28)
• Booth, D. R. et al., 2010. Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis [Letter]. Nature Genetics 42 (6), pp.469-470. (10.1038/ng0610-469)
• Ingram, G. et al. 2010. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. European Journal of Neurology 17 (11), pp.1386-1389. (10.1111/j.1468-1331.2010.03083.x)
• Ingram, G. et al. 2010. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. Journal of Neuroimmunology 223 (1-2), pp.124-127. (10.1016/j.jneuroim.2010.03.014)
• Ingram, G. and Robertson, N. 2010. The association between Anti-EBNA-1 IgG and multiple sclerosis clinical disease activity - response. European Journal of Neurology 17 (10), pp.e96. (10.1111/j.1468-1331.2010.03159.x)
• Marsh, E. A. et al. 2010. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. Journal of Neurology 257 (6), pp.913-919. (10.1007/s00415-009-5437-3)

2009

• De Silva, R. et al., 2009. Management of ataxias: guidelines on best clinical practice. Documentation. London: Ataxia. Available at: https://www.acpin.net/pdfs/Ataxia_Guidelines.pdf.
• Wickremaratchi, M. M. et al. 2009. Prevalence and age of onset of Parkinson's disease in Cardiff: A community based cross sectional study and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry 80 (7), pp.805-807. (10.1136/jnnp.2008.162222)
• Ban, M. et al., 2009. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. European Journal of Human Genetics 17 (10), pp.1309-1313. (10.1038/ejhg.2009.41)
• Booth, D. R. et al., 2009. The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes and Immunity 10 (1), pp.11-14. (10.1038/gene.2008.83)
• Hirst, C. L. et al. 2009. Increasing prevalence and incidence of multiple sclerosis in South East Wales. Journal of Neurology, Neurosurgery & Psychiatry 80 (4), pp.386-391. (10.1136/jnnp.2008.144667)
• Ingram, G. et al. 2009. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinical and Experimental Immunology 155 (2), pp.128-139. (10.1111/j.1365-2249.2008.03830.x)
• Joseph, F. G. et al., 2009. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. Journal of Neurology, Neurosurgery & Psychiatry 80 (3), pp.292-296. (10.1136/jnnp.2008.150896)
• Wardle, M. et al. 2009. The genetic aetiology of late-onset chronic progressive cerebellar ataxia. Journal of Neurology 256 (3), pp.343-348. (10.1007/s00415-009-0015-2)
• Wardle, M. , Morris, H. R. and Robertson, N. 2009. Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: a systematic review. Movement Disorders 24 (11), pp.1636-1640. (10.1002/mds.22642)
• Wardle, M. , Muzaimi, M. B. and Robertson, N. 2009. Late onset cerebellar ataxia: Natural history and prognosis [Abstract]. Journal of Neurology Neurosurgery and Psychiatry 80 (1), pp.106-106.
• Wilkins, A. et al., 2009. Very long chain fatty acid levels in patients diagnosed with multiple sclerosis. Multiple Sclerosis Journal 15 (12), pp.1525-1527. (10.1177/1352458509351731)

2008

• Hafler, J. P. et al., 2008. CD226 Gly307Ser association with multiple autoimmune diseases. Genes and Immunity 10 (1), pp.5-10. (10.1038/gene.2008.82)
• Segal, B. M. et al., 2008. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet Neurology 7 (9), pp.796-804. (10.1016/S1474-4422(08)70173-X)
• 2008. Refining genetic associations in multiple sclerosis. Lancet Neurology 7 (7), pp.567-569. (10.1016/S1474-4422(08)70122-4)
• Hirst, C. L. et al. 2008. Contribution of relapses to disability in multiple sclerosis. Journal of Neurology 255 (2), pp.280-287. (10.1007/s00415-008-0743-8)
• Hirst, C. L. et al. 2008. Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis. Journal of Neurology, Neurosurgery and Psychiatry 79 (10), pp.1137-1143. (10.1136/jnnp.2007.133785)
• Hirst, C. L. et al. 2008. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. Journal of Neurology 255 (2), pp.231-238. (10.1007/s00415-008-0696-y)
• Hirst, C. L. et al. 2008. Survival and cause of death in multiple sclerosis: a prospective population-based study. Journal of Neurology, Neurosurgery & Psychiatry 79 (9), pp.1016-1021. (10.1136/jnnp.2007.127332)
• Wardle, M. et al., 2008. Dentatorubral pallidoluysian atrophy in South Wales. Journal of Neurology, Neurosurgery and Psychiatry 79 (7), pp.804-807. (10.1136/jnnp.2007.128074)

2007

• Wiles, C. et al., 2007. Clinical skills evaluation of trainees in a neurology department. Clinical Medicine 7 (4), pp.365-369. (10.7861/clinmedicine.7-4-365)
• De Silva, R. et al., 2007. Management of ataxias: guidelines on best clinical practice. London: Ataxia.org.uk.
• Majounie, E. et al. 2007. Case control analysis of repeat expansion size in ataxia. Neuroscience Letters 429 (1), pp.28-32. (10.1016/j.neulet.2007.09.055)
• Wardle, M. and Robertson, N. 2007. Chronic progressive late onset cerebellar ataxia [Review]. Advances in Clinical Neuroscience and Rehabilitation 7 (2), pp.6-12.

2006

• Hirst, C. et al., 2006. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). Journal of Neurology, Neurosurgery & Psychiatry 77 (6), pp.800-802. (10.1136/jnnp.2005.076869)

2005

• Pearson, O. R. et al. 2005. Can actual real-life mobility be measured? (Abstract). Journal of the Neurological Sciences 238 (S1), pp.S347-S348.

2004

• Muzaimi, M. B. et al., 2004. Population based study of late onset cerebellar ataxia in south east Wales. Journal of Neurology, Neurosurgery and Psychiatry 75 (8), pp.1129-1134. (10.1136/jnnp.2003.014662)

2003

• Zajicek, J. et al., 2003. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. The Lancet 362 (9395), pp.1517-1526. (10.1016/S0140-6736(03)14738-1)
• Muzaimi, M. B. et al., 2003. Task specific focal dystonia: a presentation of spinocerebellar ataxia type 6. Journal of Neurology, Neurosurgery & Psychiatry 74 (10), pp.1444-1445. (10.1136/jnnp.74.10.1444)
• Vincent, A. et al., 2003. Evidence of underdiagnosis of myasthenia gravis in older people. Journal of Neurology, Neurosurgery & Psychiatry 74 (8), pp.1105-1108. (10.1136/jnnp.74.8.1105)

2001

• Chataway, J. et al., 2001. Multiple sclerosis in sibling pairs: an analysis of 250 families. Journal of Neurology, Neurosurgery and Psychiatry 71 (6), pp.757-761. (10.1136/jnnp.71.6.757)
• Hupperts, R. et al., 2001. Patterns of disease in concordant parent-child pairs with multiple sclerosis. Neurology 57 (2), pp.290-295.
• Hillier, C. and Robertson, N. 2001. Practical management of headache in primary care medicine. British Journal of Hospital Medicine 62 (11), pp.634-641.

2000

• Robertson, N. 2000. Enumerating neurology. Brain 123 (4), pp.663-664. (10.1093/brain/123.4.663)

1999

• Hennessey, A. et al., 1999. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. Journal of Neurology 246 (11), pp.1027-1032. (10.1007/s004150050508)
• McNamara, B. et al., 1999. Paraneoplastic sensory neuropathy and Purkinje cell antibodies [Letter]. Muscle & Nerve 22 (10), pp.1466-1467. (10.1002/(SICI)1097-4598(199910)22:10<1466::AID-MUS20>3.0.CO;2-D)
• Robertson, N. , Compston, D. A. and Kirkpatrick, P. 1999. Moyamoya disease presenting as Valsalva related partial seizures. Journal of Neurology, Neurosurgery & Psychiatry 66 (1), pp.111. (10.1136/jnnp.66.1.111)
• Robertson, N. 1999. An Atlas of Multiple Sclerosis [Book Review]. Journal of Neurology, Neurosurgery & Psychiatry 67 (1), pp.132-132. (10.1136/jnnp.67.1.132a)

1998

• Robertson, N. P. et al. 1998. Adult polyglucosan body disease associated with an extrapyramidal syndrome. Journal of Neurology, Neurosurgery & Psychiatry 65 (5), pp.788-790. (10.1136/jnnp.65.5.788)
• Chataway, J. et al., 1998. The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain 121 (10), pp.1869-1887. (10.1093/brain/121.10.1869)
• Robertson, N. , Deans, J. and Compston, D. A. 1998. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. Journal of Neurology, Neurosurgery & Psychiatry 65 (4), pp.492-496. (10.1136/jnnp.65.4.492)
• Robertson, N. , Shaunak, S. and Compston, D. A. 1998. Urgent neurology out-patient referrals from primary health care physicians. QJM: An International Journal of Medicine 91 (4), pp.309-313. (10.1093/qjmed/91.4.309)

1997

• Robertson, N. et al. 1997. Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. The Lancet 349 (9065), pp.1587-1590. (10.1016/S0140-6736(96)07317-5)

1996

• Chalmers, R. M. et al., 1996. Sequence of mitochondrial DNA in patients with multiple sclerosis. Annals of Neurology 40 (2), pp.239-243. (10.1002/ana.410400216)
• Robertson, N. et al. 1996. Clinical concordance in sibling pairs with multiple sclerosis. Neurology 47 (2), pp.347-352. (10.1212/WNL.47.2.347)
• Sawcer, S. et al., 1996. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genetics 13 (4), pp.464-468. (10.1038/ng0896-464)
• Robertson, N. et al. 1996. Multiple sclerosis in south Cambridgeshire: incidence and prevalence based on a district register. Journal of Epidemiology & Community Health 50 (3), pp.274-279. (10.1136/jech.50.3.274)
• Robertson, N. et al. 1996. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain 119 (2), pp.449-455. (10.1093/brain/119.2.449)

1995

• Wood, N. W. et al., 1995. Susceptibility to multiple sclerosis and the immunoglobulin heavy chain variable region. Journal of Neurology 242 (10), pp.677-682. (10.1007/BF00866919)
• Wood, N. W. et al., 1995. The T-cell receptor beta locus and susceptibility to multiple sclerosis. Neurology 45 (10), pp.1859-1863. (10.1212/WNL.45.10.1859)
• Robertson, N. P. et al. 1995. Multiple sclerosis in the north Cambridgeshire districts of East Anglia. Journal of Neurology, Neurosurgery & Psychiatry 59 (1), pp.71-76. (10.1136/jnnp.59.1.71)
• Chalmers, R. M. et al., 1995. Sequence of the human homologue of a mitochondrially encoded murine transplantation antigen in patients with multiple sclerosis. Journal of Neurology 242 (5), pp.332-334. (10.1007/BF00878877)
• Kellar-Wood, H. F. et al., 1995. Multiple sclerosis and the HLA-D region: linkage and association studies. Journal of Neuroimmunology 58 (2), pp.183-190. (10.1016/0165-5728(95)00015-T)
• Compston, D. A. et al., 1995. Genes and susceptibility to multiple sclerosis [Editorial]. Acta Neurologica Scandinavica Supplementum 161 , pp.43-51. (10.1111/j.1600-0404.1995.tb05855.x)
• Robertson, N. and Compston, A. 1995. Surveying multiple sclerosis in the United Kingdom [Editorial]. Journal of Neurology, Neurosurgery & Psychiatry 58 (1), pp.2-6.
• Robertson, N. et al. 1995. Strategies for the identification of susceptibility genes in multiple sclerosis [Editorial]. The International Ms Journal 2 , pp.19-28.

1994

• Wood, N. W. et al., 1994. No linkage or association between multiple sclerosis and the myelin basic protein gene in affected sibling pairs. Journal of Neurology, Neurosurgery & Psychiatry 57 (10), pp.1191-1194. (10.1136/jnnp.57.10.1191)
• Kellar-Wood, H. et al., 1994. Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. Annals of Neurology 36 (1), pp.109-112. (10.1002/ana.410360121)